Long-term results of GH treatment in Silver-Russell syndrome (SRS): Do they benefit the same as non-SRS short-SGA?

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 5, 2016, Pages 2105-2112

  Smeets, Carolina C J ^a   Zandwijken, G R J ^b   Renes, J S ^a   Hokken Koelega, A C S ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Dutch Growth Research Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

ARTICLE; BODY HEIGHT; CHILD; CHROMOSOME 7; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; GROWTH RATE; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; SHORT COURSE THERAPY; SILVER RUSSELL SYNDROME; SMALL FOR DATE INFANT; TREND STUDY; UNIPARENTAL DISOMY CHROMOSOME 7; ADOLESCENT; COMPARATIVE STUDY; DRUG EFFECTS; GROWTH DISORDERS; PROSPECTIVE STUDY; SILVER-RUSSELL SYNDROME; TREATMENT OUTCOME;

ADOLESCENT; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INFANT, SMALL FOR GESTATIONAL AGE; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; SILVER-RUSSELL SYNDROME; TREATMENT OUTCOME;

EID: 84969795583     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-4273     Document Type: Article

References (31)

1. Russell A. A syndrome of intra-uterine dwarfism recognizable at birth with cranio-facial dysostosis, disproportionately short arms, and other anomalies (5 examples). Proc R Soc Med. 1954;47:1040-1044.
2. Silver HK, Kiyasu W, George J, Deamer WC. Syndrome of congenital hemihypertrophy, shortness of stature, and elevated urinary gonadotropins. Pediatrics. 1953;12:368-376.
3. Wollmann HA, Kirchner T, Enders H, Preece MA, Ranke MB. Growth and symptoms in Silver-Russell syndrome: review on the basis of 386 patients. Eur J Pediatr. 1995;154:958-968.
4. Marsaud C, Rossignol S, Tounian P, Netchine I, Dubern B. Prevalence and management of gastrointestinal manifestations in Silver-Russell syndrome. Arch Dis Child. 2015;100:353-358.
5. Azzi S, Abi Habib W, Netchine I. Beckwith-Wiedemann and Russell-Silver syndromes: from new molecular insights to the comprehension of imprinting regulation. Curr Opin Endocrinol Diabetes Obes. 2014;21:30-38.
6. Gicquel C, Rossignol S, Cabrol S, et al. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. Nat Genet. 2005;37:1003-1007.
7. Eggermann T, Meyer E, Obermann C, et al. Is maternal duplication of 11p15 associated with Silver-Russell syndrome? J Med Genet. 2005;42:e26.
8. Fisher AM, Thomas NS, Cockwell A, et al. Duplications of chromosome 11p15 of maternal origin result in a phenotype that includes growth retardation. Hum Genet. 2002;111:290-296.
9. Begemann M, Zirn B, Santen G, et al. Paternally inherited IGF2 mutation and growth restriction. N Engl J Med. 2015;373:349-356.
10. Brioude F, Oliver-Petit I, Blaise A, et al. CDKN1C mutation affecting the PCNA-binding domain as a cause of familial Russell Silver syndrome. J Med Genet. 2013;50:823-830.
11. Turner CL, Mackay DM, Callaway JL, et al. Methylation analysis of 79 patients with growth restriction reveals novel patterns of methylation change at imprinted loci. Eur J Hum Genet. 2010;18:648-655.
12. Dias RP, Bogdarina I, Cazier JB, et al. Multiple segmental uniparental disomy associated with abnormal DNA methylation of imprinted loci in Silver-Russell syndrome. J Clin Endocrinol Metab. 2012;97:E2188-E2193.
13. Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab. 2003;88:3584-3590.
14. Toumba M, Albanese A, Azcona C, Stanhope R. Effect of long-term growth hormone treatment on final height of children with Russell-Silver syndrome. Horm Res Paediatr. 2010;74:212-217.
15. Azzi S, Salem J, Thibaud N, et al. A prospective study validating a clinical scoring system and demonstrating phenotypical-genotypical correlations in Silver-Russell syndrome. J Med Genet. 2015;52: 446-453.
16. Binder G, Liebl M, Woelfle J, Eggermann T, Blumenstock G, Schweizer R. Adult height and epigenotype in children with Silver-Russell syndrome treated with GH. Horm Res Paediatr. 2013;80: 193-200.
17. Wakeling EL, Amero SA, Alders M, et al. Epigenotype-phenotype correlations in Silver-Russell syndrome. J Med Genet. 2010;47: 760-768.
18. Usher R, McLean F. Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr. 1969;74:901-910.
19. Fredriks AM, van Buuren S, Burgmeijer RJ, et al. Continuing positive secular growth change in the Netherlands 1955-1997. Pediatr Res. 2000;47:316-323.
20. Fredriks AM. Growth Diagrams. 2nd ed. Houten, The Netherlands: Bohn Stafleu van Loghum; 2002.
21. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976;51:170-179.
22. Tanner JM, Whitehouse RH, Carmeron N, Marshall WA, Healy MJ, Goldstein H. Assessment of Skeletal Maturity and Prediction of Adult Height (TW2-Method). 2nd ed. London: Academic Press; 1983.
23. Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM. Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res. 1998;50:166-176.
24. Carel JC, Chatelain P, Rochiccioli P, Chaussain JL. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. J Clin Endocrinol Metab. 2003;88:1587-1593.
25. Dahlgren J, Wikland KA, Swedish Study Group for Growth Hormone Treatment. Final height in short children born small for gestational age treated with growth hormone. Pediatr Res. 2005;57: 216-222.
26. Renes JS, Willemsen RH, Mulder JC, et al. New insights into factors influencing adult height in short SGA children: results of a large multicentre growth hormone trial. Clin Endocrinol (Oxf). 2015;82:854-861.
27. Rakover Y, Dietsch S, Ambler GR, Chock C, Thomsett M, Cowell CT. Growth hormone therapy in Silver Russell syndrome: 5 years experience of the Australian and New Zealand Growth database (OZGROW). Eur J Pediatr. 1996;155:851-857.
28. Müller A, Soellner L, Binder G, Begemann M, Eggermann T. No major contribution of IGF2 variants to the etiology of sporadic 11p15-associated imprinting disorders. Am J Med Genet A. 2016; 170:283-284.
29. Eggermann T, Binder G, Brioude F, et al. CDKN1C mutations: two sides of the same coin. Trends Mol Med. 2014;20:614-622.
30. Obermann C, Meyer E, Prager S, Tomiuk J, Wollmann HA, Eggermann T. Searching for genomic variants in IGF2 and CDKN1C in Silver-Russell syndrome patients. Mol Genet Metab. 2004;82:246-250.
31. Binder G, Seidel AK, Martin DD, et al. The endocrine phenotype in Silver-Russell syndrome is defined by the underlying epigenetic alteration. J Clin Endocrinol Metab. 2008;93:1402-1407.